Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of high risk patients with nasopharyngeal carcinoma compared with those treated with chemo-radiotherapy alone.

Trial Details

NCT ID

NCT04453826

Phase

PHASE3

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

Camrelizumab plus chemo-radiotherapy
Chemo-radiotherapy alone

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25
Shaoguan, Guangdong, China|24.8,113.58333
Zhongshan, Guangdong, China|22.52306,113.37912
Zhuhai, Guangdong, China|22.27694,113.56778

Key Eligibility Criteria

Histologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or type III).
Staged as T4N0-2M0,T1-4N3M0 (stage IVa) at diagnosis (according to the 8th AJCC edition).
Staged as T1-3N1-2M0, T2-3N0M0 (stage II-III) with SD/PD according to RECIST criteria or EBV DNA of \>0 copies/mL after 3 cycles of GP induction ch…
Aged between 18-70 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →